Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease

First Posted Date
2008-11-25
Last Posted Date
2015-04-01
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
32
Registration Number
NCT00797056
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People

First Posted Date
2008-11-19
Last Posted Date
2011-10-26
Lead Sponsor
Fundacion GESICA
Target Recruit Count
30
Registration Number
NCT00793754
Locations
🇦🇷

Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina

Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2008-11-13
Last Posted Date
2011-12-08
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
1
Registration Number
NCT00790452
Locations
🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers

First Posted Date
2008-10-23
Last Posted Date
2008-10-23
Lead Sponsor
Research Associates of New York, LLP
Target Recruit Count
125
Registration Number
NCT00778193
Locations
🇺🇸

Research Associates of New York, New York, New York, United States

The Clopidogrel and Aspirin After Surgery for Coronary Artery Disease

First Posted Date
2008-10-21
Last Posted Date
2008-10-21
Lead Sponsor
China National Center for Cardiovascular Diseases
Target Recruit Count
300
Registration Number
NCT00776477
Locations
🇨🇳

Institute of cardiovascular diseases,Fuwai hospital, Beijing, Beijing, China

Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation

First Posted Date
2008-10-21
Last Posted Date
2016-08-30
Lead Sponsor
Deutsches Herzzentrum Muenchen
Target Recruit Count
614
Registration Number
NCT00776633
Locations
🇩🇪

Deutsches Herzzentrum München, Munich, Germany

🇩🇰

Aarhus University Hospital, Aarhus, Denmark

🇩🇪

1. Medizinische Klinik, Klinikum rechts der Isar, München, Germany

Anti-Inflammatory and Anti-Platelet Effect of Clopidogrel and Aspirin vs Aspirin Alone in Symptomatic Polyvascular Disease and in Patients With Multiple Recurrent Cardiovascular Events

First Posted Date
2008-10-20
Last Posted Date
2008-10-20
Lead Sponsor
Catholic University of the Sacred Heart
Target Recruit Count
213
Registration Number
NCT00775762
Locations
🇮🇹

Catholic University of the Sacred Heart, Department of Cardiovascular Medicine, Rome, Italy

The Effects of Omega-3 Fatty Acids on Aspirin Resistance

First Posted Date
2008-10-15
Last Posted Date
2012-11-06
Lead Sponsor
University of Rochester
Target Recruit Count
27
Registration Number
NCT00771914
Locations
🇺🇸

University of Rochester School of Medicine and Dentistry, Rochester, New York, United States

Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2008-09-08
Last Posted Date
2017-04-12
Lead Sponsor
Vanderbilt University
Target Recruit Count
51
Registration Number
NCT00748371
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

Women With Chest Pain and Normal Coronary Arteries Study

First Posted Date
2008-08-28
Last Posted Date
2023-12-12
Lead Sponsor
Northwestern University
Target Recruit Count
3
Registration Number
NCT00743197
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath